Edition:
United Kingdom

Zealand Pharma A/S (ZEAL.OQ)

ZEAL.OQ on NASDAQ Stock Exchange Global Select Market

18.25USD
18 Apr 2019
Change (% chg)

$-0.11 (-0.60%)
Prev Close
$18.36
Open
$18.34
Day's High
$18.34
Day's Low
$18.25
Volume
273
Avg. Vol
2,130
52-wk High
$20.00
52-wk Low
$11.30

Latest Key Developments (Source: Significant Developments)

Zealand Pharma And Alexion Announce Collaboration
Wednesday, 20 Mar 2019 

March 20 (Reuters) - Zealand Pharma A/S ::REG-ALEXION AND ZEALAND PHARMA ANNOUNCE COLLABORATION TO DISCOVER AND DEVELOP PEPTIDE THERAPIES FOR COMPLEMENT-MEDIATED DISEASES.ZEALAND PHARMA TO RECEIVE UPFRONT PAYMENT OF $25 MILLION AND EQUITY INVESTMENT OF $15 MILLION.ZEALAND PHARMA WITH POTENTIAL FOR ADDITIONAL MILESTONE-DEPENDENT AND ROYALTY PAYMENTS.AGREEMENT PROVIDES POTENTIAL FOR DEVELOPMENT-RELATED MILESTONES OF UP TO $115 MILLION.AGREEMENT PROVIDES AS WELL AS UP TO $495 MILLION IN SALES-RELATED MILESTONES AND POTENTIAL FOR HIGH SINGLE- TO LOW DOUBLE-DIGIT ROYALTY PAYMENTS.  Full Article

Zealand Pharma: Britt Meelby Jensen To Resign From Position As President And CEO
Monday, 26 Nov 2018 

Nov 26 (Reuters) - Zealand Pharma A/S ::REG-ZEALAND PHARMA ANNOUNCES CHANGE IN EXECUTIVE MANAGEMENT.REG-ZEALAND PHARMA ANNOUNCES CHANGE IN EXECUTIVE MANAGEMENT.BRITT MEELBY JENSEN HAS TODAY DELIVERED HER NOTICE TO RESIGN FROM HER POSITION AS PRESIDENT AND CEO.WILL REMAIN IN HER POSITION WITH ZEALAND PHARMA UNTIL FURTHER NOTICE..PROCESS OF FINDING A REPLACEMENT FOR BRITT MEELBY JENSEN WILL COMMENCE IMMEDIATELY..  Full Article

Zealand Pharma Achieves Primary And Key Secondary Endpoints In Pivotal Phase 3 Trial With Dasiglucagon For Severe Hypoglycemia
Tuesday, 18 Sep 2018 

Sept 18 (Reuters) - Zealand Pharma A/S ::ZEALAND PHARMA ACHIEVES PRIMARY AND KEY SECONDARY ENDPOINTS IN PIVOTAL PHASE 3 TRIAL WITH DASIGLUCAGON FOR SEVERE HYPOGLYCEMIA.ZEALAND PHARMA A/S - 99% OF PATIENTS ON DASIGLUCAGON RECOVERED FROM LOW BLOOD GLUCOSE WITHIN 15 MINUTES.ZEALAND PHARMA A/S - OVERALL, NO SAFETY CONCERNS WERE RAISED FOR DASIGLUCAGON WITHIN THE TRIAL.ZEALAND PHARMA A/S - NAUSEA AND VOMITING WERE REPORTED WITH SIMILAR NUMBERS FOR DASIGLUCAGON AND GLUCAGEN.ZEALAND PHARMA A/S - WILL SOON INITIATE A PHASE 3 TRIAL IN PEDIATRIC DIABETES PATIENTS, WHICH IS EXPECTED TO COMPLETE IN MID-2019.  Full Article

Zealand Q1 Net Sales Of Soliqua 100/33 And Lyxumia/Adlyxin At EUR 14.5 Mln
Friday, 27 Apr 2018 

April 27 (Reuters) - ZEALAND PHARMA A/S ::REG-ZEALAND ANNOUNCES NET SALES OF SOLIQUA® 100/33 AND LYXUMIA®/ADLYXIN® FOR THE FIRST QUARTER OF 2018.NET SALES OF SOLIQUA(®) 100/33 AND LYXUMIA(®)/ADLYXIN(®) OF EUR 14.5 MILLION/USD 17.9 MILLION IN Q1 2018.  Full Article

Zealand Announces Successful End-Of-Phase 2 Meeting With FDA On Glepaglutide For Short Bowel Syndrome
Thursday, 26 Apr 2018 

April 26 (Reuters) - Zealand Pharma A/S ::ZEALAND ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH FDA ON GLEPAGLUTIDE FOR SHORT BOWEL SYNDROME.SAYS PIVOTAL PHASE 3 TRIAL IS ON TRACK FOR INITIATION IN Q3 2018.ZEALAND EXPECTS TO INITIATE PIVOTAL PHASE 3 TRIAL IN Q3 2018.SCIENTIFIC ADVICE WITH EUROPEAN MEDICINES AGENCY (EMA) IS ONGOING WITH AN EXPECTED OUTCOME BY MID-2018.  Full Article

Zealand And Roche Diabetes Care Enter Phase 3 Study Collaboration For Treatment Of Congenital Hyperinsulinism With Dasiglucagon
Wednesday, 11 Apr 2018 

April 11 (Reuters) - Zealand Pharma A/S - Co Is Responsible For Conducting Phase 3 Trials, While Roche Diabetes Care Provides Its Accu ::ZEALAND AND ROCHE DIABETES CARE ENTER PHASE 3 STUDY COLLABORATION FOR TREATMENT OF CONGENITAL HYPERINSULINISM WITH DASIGLUCAGON.SURGICAL TREATMENT FOR CHILDREN WITH CHI.PHASE 3 TRIALS OF DASIGLUCAGON ARE SET TO START IN SECOND HALF OF 2018.CHEK COMBO PUMP SYSTEM FOR STUDY.  Full Article

Zealand Pharma Enters Collaboration Agreement With Roche Diabetes Care
Wednesday, 11 Apr 2018 

April 11 (Reuters) - ZEALAND PHARMA A/S ::HAS ENTERED A COLLABORATION AGREEMENT WITH ROCHE DIABETES CARE.ZEALAND RESPONSIBLE FOR CONDUCTING PHASE 3 TRIALS, ROCHE DIABETES CARE PROVIDES ITS ACCU-CHEK COMBO PUMP SYSTEM.  Full Article

Zealand Pharma: Positive Results From First Phase 3 Trial For Treatment Of Severe Hypoglycemia
Tuesday, 20 Mar 2018 

March 20 (Reuters) - ZEALAND PHARMA A/S ::REG-ZEALAND PHARMA'S FIRST PHASE 3 TRIAL WITH DASIGLUCAGON FOR TREATMENT OF SEVERE HYPOGLYCEMIA SUCCESSFULLY MEETS ITS PRIMARY OBJECTIVE.‍RESULTS CONFIRM DASIGLUCAGON'S SAFETY PROFILE WITH NO TREATMENT-INDUCED OR TREATMENT-BOOSTED ANTI-DRUG ANTIBODIES​.‍ADDITIONAL RESULTS FROM THIS PHASE 3 TRIAL WILL BE AVAILABLE IN Q2 2018​.‍ADDITIONAL RESULTS FROM TRIAL ARE EXPECTED IN Q2 2018​.‍RESULTS FROM PIVOTAL PHASE 3 EFFICACY TRIAL ARE EXPECTED IN H2 2018.​.  Full Article

Zealand Pharma FY Net Loss At DKK 272.3 Million​
Wednesday, 7 Mar 2018 

March 7 (Reuters) - ZEALAND PHARMA A/S ::FY 2017 REVENUE DKK ‍​ 139.8 MILLION VERSUS DKK 234.8 MILLION YEAR AGO.‍FY NET LOSS FOR YEAR OF DKK 272.3 MILLION​.NO DIVIDEND HAS BEEN PROPOSED FOR 2017.FOR 2018, ZEALAND EXPECTS A CONTINUED INCREASE IN ROYALTY PAYMENTS FROM SANOFI.‍​.NET OPERATING EXPENSES IN 2018 ARE EXPECTED TO BE WITHIN THE DKK 475-495 MILLION RANGE.‍​.  Full Article

Zealand Pharma And Uniquest Collaborate To Develop Novel Drug Candidates
Tuesday, 20 Feb 2018 

Feb 20 (Reuters) - Zealand Pharma A/S ::REG-ZEALAND PHARMA AND UNIQUEST COLLABORATE TO DEVELOP NOVEL DRUG CANDIDATES FOR GASTROINTESTINAL DISEASES.  Full Article